Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 3/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15399318 | 1.00 | MEN1 (0.53) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL15399147 | 1.00 | MEN1 (0.53) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL14636135 | 0.92 | MEN1 (0.51) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1468742 | 0.92 | MEN1 (0.51) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL631455 | 0.92 | MEN1 (0.59) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL26043861 | 0.90 | SMN1; SMN2 (0.54) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL26043859 | 0.90 | SMN1; SMN2 (0.54) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL26043854 | 0.90 | SMN1; SMN2 (0.54) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL3919116 | 0.89 | MEN1 (0.55) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL631190 | 0.88 | SMN1; SMN2 (0.51) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551296-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | Pfizer Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024218686-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024009191-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-11472810-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-10-18 | — | — | US | disclosed |
| CN-114007695-A | As AM2Heterocyclic spiro-compounds as receptor inhibitors | 谢菲尔德大学 | 2022-02-01 | — | — | CN | disclosed |
| EP-3880308-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | The University Of Sheffield (GB) | 2021-09-22 | — | — | EP | disclosed |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2021-08-05 | — | — | US | disclosed |
| US-10912773-B2 | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-02-09 | — | — | US | disclosed |
| US-10905688-B2 | Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-02-02 | — | — | US | disclosed |
| US-10858362-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-12-08 | — | — | US | disclosed |
| US-8178131-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2420499-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as potent PARP inhibitors | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2307409-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20110070317-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2009140320-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| US-7550603-B2 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBOTT LABORATORIES INC. (US) | 2009-06-23 | — | — | US | disclosed |
| CN-101155797-A | 1H-benzimidazole-4-carboxamide compounds substituted at the 2-position with a quaternary carbon atom are potent PARP inhibitors | ABBOTT LAB (US) | 2008-04-02 | — | — | CN | disclosed |
| EP-1869011-A2 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006110816-A2 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858362-B2 | Imidazopyrazinones as PDE1 inhibitors | PDE12, PDE4A, PDE5A | MEN1 3719/4885KMT2A 1107/4885NPSR1 1625/4885 |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | PDE12, PDE4A, PDE5A | MEN1 3719/4885KMT2A 1107/4885NPSR1 1625/4885 |
| US-11472810-B2 | Imidazopyrazinones as PDE1 inhibitors | PDE12, PDE4A, PDE5A | MEN1 3719/4885KMT2A 1107/4885NPSR1 1625/4885 |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | PARP1, PARP2, PARP4 | MEN1 3097/4885KMT2A 595/4885NPSR1 4421/4885 |
| US-20110070317-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | MEN1 1853/4885KMT2A 2694/4885NPSR1 4681/4885 |
| US-10912773-B2 | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors | PDE5A, PDE3A, PDE12 | MEN1 2645/4885KMT2A 1427/4885NPSR1 1792/4885 |
| US-10905688-B2 | Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors | PDE1A, PDE12, PDE1B | MEN1 4457/4885KMT2A 1168/4885NPSR1 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.